<DOC>
	<DOCNO>NCT01048255</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , efficacy VX-765 subject Treatment-resistant Partial Epilepsy</brief_summary>
	<brief_title>Study VX-765 Subjects With Treatment-resistant Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Subjects male female age 18 64 year ( inclusive ) body mass index 18 35 ( kg/m2 ) Subjects must diagnosis history treatment resistant partial onset seizure take 1 4 concomitant antiepileptic drug ( AED ) . Treatment resistance define failure achieve seizure freedom despite adequate use 2 different AEDs . All AED dos must remain stable 4 week prior Screening Visit throughout entire study Subjects must least 1 electroencephalogram ( EEG ) consistent partial epilepsy brain magnetic resource imaging ( MRI ) compute tomography ( CT ) scan within 5 year Screening Visit negative confounding condition Subjects must least 6 observable partial seizure 6 week prior randomization , least 1 seizure per week 3 6 week within Baseline Period Subjects male female must agree use acceptable contraceptive method define protocol Subjects otherwise good health Subjects history nonepileptic transient alteration consciousness Subjects history status epilepticus past 12 month Subjects whose seizure frequency quantify Subjects significant medical illness include kidney , liver , pulmonary gastrointestinal disease ; unstable poorly control condition Subjects clinically significant psychiatric illness Subjects positive drug screen ( exclude allow prescribed medication ) history alcoholism drug addiction within past 2 year Males subject female partner childbearing potential agree use medically approve method birth control Male subject female partner pregnant , nursing , plan become pregnant study period , within 90 day last dose study drug Female subject pregnant lactating , reproductive potential agree use medically approve birthcontrol method Subjects current prior history illness preclude immunomodulatory therapy ( e.g . history recurrent infection ) Subjects active hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) Subjects participated clinical trial involve investigational product device receive last dose study drug within 45 day 5 halflives Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>